Research ExplorerJournalsANTI-CANCER DRUG Publications

ANTI-CANCER DRUG

1 - 10 out of 10Page size: 50

Publications

  1. 2019

  2. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

    Bischoff, J., Barinoff, J., Mundhenke, C., Bauerschlag, D. O., Costa, S-D., Herr, D., Lübbe, K., Marmé, F., Maass, N., von Minckwitz, G., Grischke, E-M., Müller, V., Schmidt, M., Gerber, B., Kümmel, S., Schumacher, C., Krabisch, P., Seiler, S., Thill, M., Nekljudova, V. & Loibl, S., 04.2019, In: ANTI-CANCER DRUG. 30, 4, p. 394-401 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. 2016

  4. Activity of nintedanib in germ cell tumors

    Steinemann, G., Jacobsen, C., Gerwing, M., Hauschild, J., Amsberg, G., Höpfner, M., Nitzsche, B. & Honecker, F., 27.02.2016, In: ANTI-CANCER DRUG. 27, 2, p. 89-98

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. 2010

  6. Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?

    El-Awady, R. A., Saleh, E. M. & Dahm-Daphi, J., 2010, In: ANTI-CANCER DRUG. 21, 3, p. 277-287 3.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. 2009

  8. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.

    Dedes, K. J., Dedes, I., Imesch, P., von Bueren, A., André, O., Fink, D. & Fedier, A., 2009, In: ANTI-CANCER DRUG. 20, 5, p. 321-333 5.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. 2008

  10. The similarities of aromatase inhibitors outweigh the differences.

    Jänicke, F., 2008, In: ANTI-CANCER DRUG. 19, 2, p. 7-9 2.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. 2007

  12. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.

    Oechsle, K., Honecker, F., Kollmannsberger, C., Rick, O., Grünwald, V., Mayer, F., Hartmann, J. T. & Bokemeyer, C., 2007, In: ANTI-CANCER DRUG. 18, 3, p. 273-276 3.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  13. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.

    Nisticò, C., Bria, E., Cuppone, F., Fornier, M., Sperduti, I., Carpino, A., Pace, A., Cognetti, F. & Terzoli, E., 2007, In: ANTI-CANCER DRUG. 18, 6, p. 687-692 6.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  14. 2006

  15. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro.

    Freudlsperger, C., Moll, I., Schumacher, U. & Dahl, A., 2006, In: ANTI-CANCER DRUG. 17, 3, p. 325-332 3.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  16. 2004

  17. Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil

    Hartmann, J. T., Oechsle, K., Jäger, E., Reis, H. E., Haag, C., Niederle, N., Wilke, H-J., Pflüger, K-H., Batran, S. A., Büchele, T., Hofheinz, R. D., Kanz, L. & Bokemeyer, C., 06.2004, In: ANTI-CANCER DRUG. 15, 5, p. 473-7 5 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  18. Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.

    Tuinmann, G., Hegewisch-Becker, S., Zschaber, R., Kehr, A., Schulz, J. & Hossfeld, D. K., 2004, In: ANTI-CANCER DRUG. 15, 6, p. 575-579 6.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review